Amending the Order (1999:58) Banning Certain Products That Are Harmful to Health;

1. ------IND- 2005 0274 S-- EN- ------20050624 ------PROJET

Annex 3 to Decision Section 154, 12.05.2005

Order

amending the Order (1999:58) banning certain products that are harmful to health;

issued on xx August 2005.

The government rules1that the Annex to the Order (1999:58) banning certain products that are harmful to health shall be worded as follows.

This Order shall enter into force on 1 September 2005.

On behalf of the Swedish governmentMORGAN JOHANSSON

Björn Reuterstrand (Ministry of Health and Social Affairs)

Annex2

List of products that are to be regarded as harmful to health in accordance with the Act banning certain products that are harmful to health

N-methyl-l-(3,4-methylene dioxyphenyl)-2-butylamine (MBDB)
1-(3,4-methylene dioxyphenyl)-2-butylamine (BDB)
N-benzylpiperazine

4-chloro-2,5-dimethoxyamphetamine (DOC).

5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT)

5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT)

5-methoxy-alphamethyltryptamine (5-MeO-AMT)

2,5-dimethoxy-4-ethylphenethylamine (2C-E)

alpha-methyltryptamine (AMT)

2,5-dimethoxy-4-chlorophenethylamine (2C-C)

2,5-dimethoxy-4-methylphenethylamine (2C-D)

4-acetoxy-N,N-diisopropyltryptamine (4-AcO-DIPT)

4-hydroxy-N,N-diisopropyltryptamine (4-HO-DIPT)

3,4-methylenedioxymethcathinone (methylone)

4-acetoxy-N,N-methylisopropyltryptamine (4-AcO-MIPT)

4-hydroxy-N,N-diethyltryptamine (4-HO-DET)

4-hydroxy-N,N-methylisopropyltryptamine (4-HO-MIPT)

4-acetoxy-N,N-diethyltryptamine (4-AcO-DET)

Salts of the substances where these can occur.

1See Directive 98/34/EC of the European Parliament and of the Council of 22 June 1998 laying down a procedure for the provision of information in the field of technical standards and regulations (OJ L 204, 21.7.1998, p.37, Celex 398L0034), amended by European Parliament and Council Directive 98/48/EC (OJ L 217, 5.8.1998, p.18, Celex 398L0048).

2Most recent wording 2005:26.

Z

Swedish National Institute of PublicHealth / CLASSIFICATION DOCUMENT
for products harmful to health: Act 1999:42 Order 1999:58 / Ref: 830-05-0249
Draft submitted:
22.04.2005

RELATES TO

4-AcO-DET

1. Name, common name, chemical formula, CAS No

4-AcO-DET

4-Acetoxy-DET

4-Acetoxy-N,N-diethyltryptamine

Street name: Blue Mystic 3, BM3, AKA, ethacetin, ethylacybin, Psio.

2. Molecular formula, chemical structure

Molecular formula: C16H20N2O2

4-AcO-DET is a synthetic tryptamine analogue and has structural similarity to LSD and psilocybin/psilocin and even serotonin. Belongs to the indolealkylamines group. (Swedish Poisons Information Centre)

3. Physical data

Physical form: Occurs mainly as tablets and a light powder. The powder changes over time depending on storage and can end up as a black gunge.(SKL;

Molecular weight: 274.3 g/mol

4. Synthesis

No information.

5. Mode of action

After intake, 4-AcO-DET is probably converted to 4-HO-DET (compare 4-AcO-DIPT/4-HO-DIPT).4-AcO-DET belongs to the group of hallucinogens having effects similar to psilocybin/psilocin, LSD and other tryptamines.The pyrrole structure (3-(2-ethylamine)indole) in the indole ring appears to be necessary for the hallucinogenic effect.Exactly like LSD, it primarily stimulates a type of serotonin receptor known as 5-HT2, which is important, among other things, in connection with dependency effects in the brain.(Swedish Poisons Information Centre). According to information obtained, it produces a milder effect than 4-HO-DET.(

6. Method of exposure, abuse dosage

Usually taken orally, but can also be smoked. Oral abuse dosages are stated as: mild effect at 5-15 mg and strong effect at 20-40 mg. Takes approximately 20-45 minutes to take effect, possibly longer. The effect usually lasts for around 2-5 hours, but can be considerably longer, particularly in the case of overdosing, and seems to last longer than 4-HO-DET.(

7.Combination abuse

The user community has reported that a certain amount of combination abuse occurs. However, this is thought to be limited.(

8. Health risks

Risks to individuals

Dilated pupils are very characteristic of abuse/poisoning. Agitation, hyperactivity, confusion and visual hallucinations are very common as well as a mild to marked reduction in consciousness, i.e. unconsciousness.(Poisindex; Swedish Poisons Information Centre).In contrast to central nervous system stimulants (cocaine, amphetamine, ecstasy) tryptamines usually have no, or only a mild, effect on the circulation.Electrolyte imbalances have not, as yet, been detected. (Swedish Poisons Information Centre)

Risks to public health

4-AcO-DET is a relatively new substance within the abuser community.Two seizures have been made in Sweden and knowledge of the presence and use of the substance is supplemented via discussion forums on the Internet. Like other hallucinogens, an increase in abuse can be expected. (

Social risks

Like other psychedelic substances, 4-AcO-DET is considered to be able to bring to the fore latent psychological and mental health problems. The alteration to the psychological state produced by 4-AcO-DET can increase the risk of psychosis, serious accidents and violence.Both the individual and society are at risk.

9. Documented occurrence

Medicinal and industrial occurrence

There is no medicinal application of 4-AcO-DET in Sweden (Medical Products Agency). No industrial application of 4-AcO-DET is known (National Institute of Public Health; EMCDDA).

Occurrence of abuse

As far as the National Institute of Public Health is aware, 4-AcO-DET appeared on the Swedish abuse market at the end of 2003/beginning of 2004. Eight seizures were made in 2004 and one seizure was made at the beginning of 2005. The scale is so far limited, but it is thought that demand is increasing since 4-AcO-DIPT, among others, was regulated as a product harmful to health on 1 March 2005. The seizures that have been made were spread over the whole of Sweden; no geographical link can be made to use.

Reported occurrence in Sweden

SKL

RMV

Swedish Customs’ laboratory

Swedish Poisons Information Centre

CRD network

Analysed cases:

The first seizure of 4-AcO-DET was made in Örebro in February 2004. A further 7 seizures were then made during 2004 by the police authorities in Linköping, Kalmar, Dalarna, Kiruna, Jönköping. In January 2005, another seizure was made in Stockholm. All seizures have consisted of light pink 40 mg tablets, 2.4 mm thick and 5 mm in diameter.

Number of cases where body fluids have been analysed:up to and including April 2005: none.

Number of cases analysed:Up to and including April 2005: none.

Number of enquiries:

In 2004, 2 enquiries regarding 4-AcO-DET were received: one under the name BM3 and one as 4-AcO-DET. In 2005, 3 enquiries were received, of which one was under the name BM3, one under the name Psio and one under the name 4-AcO-DET.

A report was received from Linköping during autumn 2004.

Reported occurrence in the EU

Sweden is the only EU country that has reported finds of 4-AcO-DET (EMCDDA).

10. Availability

4-Aco-DET was previously sold in tablet form under the name Blue Mystic 3, BM3 and, according to the user community, also as Psio.Blue Mystic 3 and BM3 sometimes also contained 4-HO-DET, Psio may possibly be 4-AcO-DIPT.(Swedish Poisons Information Centre; SKL;

11. Abuse profile

The substance produces hallucinogenic effects, which are compared by users to psilocybin and other tryptamines such as 4-AcO-DIPT. 4-AcO-DET is used primarily by young people, both in the home environment and at large and small parties.The substance is reported to be used to complement, or as a substitute for, other drugs.(

12. Present control status

4-AcO-DET is currently a non-regulated substance in Sweden.

13. Conventions

4-AcO-DET is not found in either the Single Convention on Narcotic Drugs, 1961, or the Convention on Psychotropic Substances, 1971.

14. Other information

4-AcO-DET is monitored by the EU in accordance with the EU Joint Action on New Synthetic Drugs of 1997 (EMCDDA).

15. References

CRD network – regional drug reporting system of CAN (Swedish Council for Information on Alcohol and other Drugs)

EMCDDA – European Monitoring Centre for Drugs and Drugs Addiction

Swedish Poisons Information Centre

Medical Products Agency

RMV - forensic chemistry department of the National Board of Forensic Medicine

SKL - the National Laboratory of Forensic Science

Swedish National Institute of Public Health

Swedish Customs’ laboratory

www. erowid.org

16. Recommendation

In order to prevent 4-Acetoxi-N,N-diethyltryptamine (4-AcO-DET) being disseminated further and causing harm, the National Institute of Public Health, in consultation with the relevant bodies, recommends that the substance be included in the Order banning certain products that are harmful to health.

17. Notification to the European Commission

If the decision under point 13 results in the product being classified, the barriers to trade resulting from a ban must be taken into account.

Z

Swedish National Institute of PublicHealth / CLASSIFICATION DOCUMENT
for products harmful to health: Act 1999:42 Order 1999:58 / Ref: 830-05-0249
Draft submitted:
22.04.2005

RELATES TO

4-AcO-MIPT

1. Name, common name, chemical formula, CAS No

4-AcO-MIPT

4-Acetoxy-MIPT

4-Acetoxy-N,N-methylisopropyltryptamine

Street name:Mipracetin.

2. Molecular formula, chemical structure

Molecular formula: C16H20N2O2

4-AcO-MIPT is a synthetic tryptamine analogue and has structural similarity to LSD and psilocybin/psilocin and even serotonin. Belongs to the indolealkylamines group. (Swedish Poisons Information Centre)

3. Physical data

Molecular weight: 274.3 g/mol

4. Synthesis

No information.

5. Mode of action

After intake, 4-AcO-MIPT is probably converted to 4-HO-MIPT (compare 4-AcO-DIPT/4-HO-DIPT).
4-AcO-MIPT belongs to the group of hallucinogens having effects similar to psilocybin/psilocin, LSD and other tryptamines. The pyrrole structure (3-(2-ethylamine)indole) in the indole ring appears to be necessary for the hallucinogenic effect. Exactly like LSD, it primarily stimulates a type of serotonin receptor known as 5-HT2, which is important, among other things, in connection with dependency effects in the brain.(Swedish Poisons Information Centre)

6. Method of exposure, abuse dosage

No information.

7. Combination abuse

The user community has reported that a certain amount of combination abuse occurs. However, this is thought to be limited.(

8. Health risks

Risks to individuals

The abuser community recommends that care be taken with the substance, as it is considered to produce unpleasant effects in some people.(

Risks to public health

4-AcO-MIPT is a relatively new substance within the abuser community. There have as yet been no seizures in Sweden, but we are aware of the presence of the substance via discussion forums on the Internet.Like other hallucinogens, abuse is to be expected.(

Social risks

Like other psychedelic substances, 4-AcO-MIPT can bring to the fore latent psychological and mental health problems. The alteration to the psychological state produced by 4-AcO-MIPT can increase the risk of psychosis, serious accidents and violence. Both the individual and society are at risk.

9. Documented occurrence

Medicinal and industrial occurrence
There is no medicinal application of 4-AcO-MIPT in Sweden (Medical Products Agency). No industrial application of 4-AcO-MIPT is known (National Institute of Public Health; EMCDDA).
Occurrence of abuse
As far as the National Institute of Public Health is aware, 4-AcO-MIPT appeared on the Swedish abuse market during 2004. So far the scale is limited.As a result of the limited scale, no geographic link can be made to use.
Reported occurrence in Sweden
SKL
RMV
Swedish Customs’ laboratory
Swedish Poisons Information Centre
CRD network
Reported occurrence in the EU / Number of cases analysed:
Up to and including April 2005: none.
Number of cases where body fluids have been analysed:
Up to and including April 2005: none.
Number of cases analysed:
Up to and including April 2005: none.
No enquiries about 4-HO-MIPT have been received up to and including April 2005.
No reports of the substance have been received up to and including April 2005.
No seizures have been reported to the EU (EMCDDA) up to and including April 2005.
EU

10. Availability

No information.

11. Abuse profile

The substance produces hallucinogenic effects, which are compared by users to psilocybin, among others. It is primarily young people who use 4-AcO-MIPT.Abuse has been reported from party environments, where the substance is used to complement, or as a substitute for, other drugs.(

12. Present control status

4-AcO-MIPT is currently a non-regulated substance in Sweden.

13. Conventions

4-AcO-MIPT is not found in either the Single Convention on Narcotic Drugs, 1961, or the Convention on Psychotropic Substances, 1971.

14. Other information

4-AcO-MIPT is monitored by the EU in accordance with the EU Joint Action on New Synthetic Drugs of 1997 (EMCDDA).

15. References

CRD network – regional drug reporting system of CAN (Swedish Council for Information on Alcohol and other Drugs)

EMCDDA – European Monitoring Centre for Drugs and Drugs Addiction

Swedish Poisons Information Centre

Medical Products Agency

RMV - forensic chemistry department of the National Board of Forensic Medicine

SKL - the National Laboratory of Forensic Science

Swedish National Institute of Public Health

Swedish Customs’ laboratory

www. erowid. org

16. Recommendation

In order to prevent 4-Acetoxi-N,N-methylisopropyltryptamine (4-AcO-MIPT) being disseminated further and causing harm, the National Institute of Public Health, in consultation with the relevant bodies, recommends that the substance be included in the Order banning certain products that are harmful to health.

17. Notification to the European Commission

If the decision under point 16 results in the product being classified, the barriers to trade resulting from a ban must be taken into account.

Z

Swedish National Institute of PublicHealth / CLASSIFICATION DOCUMENT
for products harmful to health: Act 1999:42 Order 1999:58 / Ref: 830-05-0249
Draft submitted:
22.04.2005

RELATES TO

4-HO-DET

1. Name, common name, chemical formula, CAS No

4-HO-DET

4-Hydroxy-DET

4-Hydroxy-N,N-diethyltryptamine

Street name: ethocin, CZ-74, (found together with 4-AcO-DET in Blue Mystic 3 and BM3 (SKL))

CAS Number: 22204-89-3

2. Molecular formula, chemical structure

Molecular formula: C14H20N2O

4-HO-DET is a synthetic tryptamine analogue and has structural similarity to LSD and psilocybin/psilocin and even serotonin. Belongs to the indolealkylamines group.

3. Physical data

Physical form: Not as stable as its relative 4-AcO-DET, therefore 4-HO-DET can quite easily be converted.(

Molecular weight: 232.45 g/mol

Melting point:104-106 °C

4. Synthesis

No information.

5. Mode of action

4-HO-DET belongs to the group of hallucinogens having effects similar to psilocybin/psilocin, LSD and other tryptamines (Leuner & Baer 1965; Baer 1967; Leuner 1962).The pyrrole structure (3-(2-ethylamine)indole) in the indole ring appears to be necessary for the hallucinogenic effect. Exactly like LSD, it primarily stimulates a type of serotonin receptor known as 5-HT2, which is important, among other things, in connection with dependency effects in the brain. (Swedish Poisons Information Centre)

After intake, 4-AcO-DET is converted to 4-HO-DET (compare 4-AcO-DIPT/4-HO-DIPT).

6. Method of exposure, abuse dosage

Usually taken orally, but can also be smoked. Usual abuse dosage is given as 10 mg. (

7. Combination abuse

No information.

8. Health risks

Risks to individuals

According to a study conducted by Leuner and Baer in which an average of 0.20 mg/kg (0.05-0.26 mg/kg) was given and the effect lasted from 1.5 to 6 hours, feeling sick and visual hallucinations were the main occurrences. Symptoms such as hyperactivity, difficulty concentrating, confusion and auditory hallucinations also occurred.At the highest doses, psychoses and other mental health problems also arose.(Leuner & Baer 1965)

Dilated pupils are very characteristic of abuse/poisoning. Agitation, hyperactivity, confusion and visual hallucinations are very common as well as a mild to marked reduction in consciousness, i.e. unconsciousness.(Poisindex; Swedish Poisons Information Centre). In contrast to central nervous system stimulants (cocaine, amphetamine, ecstasy) tryptamines usually have no, or only a mild, effect on the circulation.Electrolyte imbalances have not, as yet, been detected. (Swedish Poisons Information Centre)

Risks to public health

4-HO-DET is a new substance within the abuser community. In 2004, one seizure of the substance was made and knowledge of its use is supplemented via discussion forums on the Internet.Use is still limited, but as a result of its similarity to 4-AcO-DET, which is thought to be used more extensively, and, like other hallucinogens, an increase in abuse can be expected.(SKL;

Social risks

Like other psychedelic substances, 4-HO-DET can bring to the fore latent psychological and mental health problems.The alteration to the psychological state produced by 4-HO-DET can increase the risk of psychosis, serious accidents and violence. Both the individual and society are at risk. (Leuner & Baer 1965)

9. Documented occurrence

Medicinal and industrial occurrence

There is no medicinal application of 4-HO-DET in Sweden (Medical Products Agency).No industrial application of 4-HO-DET is known (National Institute of Public Health; EMCDDA).

Occurrence of abuse

As far as the National Institute of Public Health is aware, 4-HO-DET appeared on the Swedish abuse market during 2004. A seizure of the substance was made towards the end of 2004, and the scale is still limited. However, in view of its similarity to 4-AcO-DET, increased demand can be expected. There is no known geographical link to use.

Reported occurrence in Sweden

SKL RMV

Swedish Customs’ laboratory

Swedish Poisons Information Centre

CRD network

Reported occurrence in the EU

EU

In October 2004, the police authority in Dalarna seized pink 50 mg tablets, 5.1 mm in diameter, containing 4-HO-DET.

Number of cases where body fluids have been analysed: Up to and including April 2005: none.

Number of cases analysed:
Up to and including April 2005: none.

No enquiries about 4-HO-DET have been received up to and including April 2005.

No reports of the substance have been received up to and including April 2005.

Sweden is the only EU country that has reported finds of 4-HO-DET (EMCDDA).

10. Availability

On the Swedish abuse market there are tablets called Blue Mystic 3 and BM3. These have been shown to contain 4-HO-DET in combination with 4-AcO-DET. (SKL)